Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | FADS1 | O60427 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL681701 | 1.00 | ALDH1A1 (0.45) | ALDH1A1MAPTHTTFADS1 | |
| SCHEMBL683095 | 0.88 | MAPT (0.46) | ALDH1A1MAPTHTT | |
| SCHEMBL682710 | 0.88 | MAPT (0.46) | ALDH1A1MAPTHTT | |
| SCHEMBL678103 | 0.82 | MAPT (0.49) | ALDH1A1MAPTHTTFADS1 | |
| SCHEMBL678815 | 0.82 | MAPT (0.49) | ALDH1A1MAPTHTTFADS1 | |
| SCHEMBL678104 | 0.82 | MAPT (0.49) | ALDH1A1MAPTHTTFADS1 | |
| SCHEMBL679330 | 0.78 | MAPT (0.50) | ALDH1A1MAPTHTT | |
| SCHEMBL679443 | 0.78 | MAPT (0.50) | ALDH1A1MAPTHTT | |
| SCHEMBL679331 | 0.78 | MAPT (0.50) | ALDH1A1MAPTHTT | |
| SCHEMBL678581 | 0.77 | MAPT (0.65) | ALDH1A1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010233-A1 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS (US) | 2012-01-12 | — | — | US | disclosed |
| US-8003692-B2 | Methods and compositions to inhibit edema factor and adenylyl cyclase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010233-A1 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | VIP, PDE3B, ADCY5 | ALDH1A1 3208/4885MAPT 4872/4885HTT 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.